Tian 2011.

Methods	This was a randomised, controlled, parallel clinical trial
Participants	1. Setting: The trial recruited participants from an outpatient department of a general hospital in Shenyang, China 2. Age: from 39 days to 20 months old 3. Sex (men/women): 28/22 4. Number of participants randomised: 60 5. T/C: 30/30
Interventions	I. Treatment group a. Oral ingestion 1. Qushi Zhiyang formula with individualised modifications 1.1 Ingredients and dosage Shigao(Gypsum fibrosum) 10 g Fuling (Poria) 10 g Yiyiren (Semen coicis) 15 g Yinchen (Herba artemisiae scopariae) 15 g Danzhuye (Herba lophatheri) 8 g Gancao(Radix glycyrrhizae) 6 g Mudanpi (Cortex moutan) 10 g Lianqiao (Fructus forsythiae) 10 g Jinyinhua (Flos lonicerae) 10 g Yejuhua (Flos chrysanthemi indici) 15 g Baixianpi (Cortex dictamni) 10 g Danggui (Radix angelicae sinensis) 10 g Huashi (Talcum) 10 g 1.2 Administration The formula was decocted twice to produce a total of 100 ml of herbal liquid. Oral ingestion of the herbal liquid was 3 times daily 1.3 Duration of treatment 4 weeks 1.4 Follow up 8 weeks after the end of treatment b. Topical application Decocted the formula above for the third time, external use of the herbal liquid twice daily II. Control group a. Oral ingestion 2. Chlorpheniramine tablet, diphenhydramine syrup, antibiotics, vitamin E, and vitamin C 2.1 Ingredients and dosage Chlorpheniramine tablet 0.35 mg per day Did not provide dosage of diphenhydramine syrup, vitamin E, and vitamin C, did not provide ingredient of antibiotics 2.2 Administration Oral ingestion of chlorpheniramine tablet 3 times daily Did not provide administration of diphenhydramine syrup, antibiotics, and vitamins 2.3 Duration of treatment 4 weeks 2.4 Follow up 8 weeks after the end of treatment b. Topical application 2. Hydrocortisone butyrate cream 2.1 Ingredients and dosage 0.1% hydrocortisone butyrate cream (dosage not provided) 2.2 Administration Once to 3 times daily 2.3 Duration of treatment 4 weeks 2.4 Follow up 8 weeks after the end of treatment
Outcomes	1. Effectiveness rate assessed at the end of the 8‐week treatment period
Notes	We contacted the corresponding trial investigator for further information (such as the randomisation method, a report of adverse events, and whether the study was a prospective design). We received no reply